Alterity Therapeutics Ltd has released a press release.
Trading Halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-510
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity Therapeutics to Present at the Biotech Showcase
- Appendix 4E and 2025 Annual Report
- Response to ASX Query Letters
- Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
- Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
Later from Alterity Therapeutics
- Alterity Therapeutics Raises A$20.0 million in Strategic Placement
- Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics